

# Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Influence of droplet size on stability, *in vivo* digestion, and oral bioavailability of**  
2 **vitamin E emulsions**

3  
4  
5  
6 **S. Parthasarathi<sup>1,2</sup>, S.P. Muthukumar<sup>3</sup> and C. Anandharamakrishnan<sup>1,2\*</sup>**

7 <sup>1</sup>Department of Food Engineering

8 CSIR-Central Food Technological Research Institute

9 Mysore-570 020, India

10  
11 <sup>2</sup>Academy of Scientific and Innovative Research (AcSIR), CSIR-CFTRI Campus, India.

12  
13 <sup>3</sup>Animal House Facility

14 CSIR-Central Food Technological Research Institute

15 Mysore-570 020, India

16  
17  
18  
19 *\* Correspondence:*

20 -----  
21 *C. Anandharamakrishnan*

22 *Ph: +91-821-2513910*

23 *Fax: +91-821-2517233*

24 *\*E-mail: anandhram@cftri.res.in*

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

## Abstract

Vitamin E ( $\alpha$ -Tocopherol) is a nutraceutical compound, shown to possess potent antioxidant and anticancer activity; however, its biological activity may be limited by poor bioavailability. Colloidal delivery systems are showing wide applications in the food and pharmaceutical industries to deliver lipophilic bioactive compounds. In this study we developed conventional and nanoemulsions of vitamin E from food grade ingredients (sunflower oil, saponin, and water) and showed nanoemulsion formulation increased the oral bioavailability than the conventional emulsion. The mean droplet diameters in nano and conventional emulsions were 0.277 and 1.285  $\mu\text{m}$  respectively. Stability of emulsion formulation with thermal processing, long-term storage at different temperatures, mechanical stress and in plasma was determined. Results showed that saponin coated nanoemulsion were stable to droplet coalescence during thermal processing (30 – 90 °C), long-term storage and mechanical stress than conventional emulsion. Biological fate of emulsion formulation were studied using male Wistar rats as animal model. Emulsion droplet stability during the passage through gastrointestinal tract was evaluated by introducing them into rat stomachs. Microscopy technique was used to investigate the structural changes during digestion. Both conventional and nanoemulsion formulation showed strong evidence of droplet flocculation and coalescence during *in vivo* digestion. *In vivo* oral bioavailability study revealed that vitamin E in nanoemulsion form enhanced 3 fold increase in AUC than the conventional emulsion. The information reported in this study will facilitate the design of colloidal delivery system using nanoemulsion formulation.

49 **Keywords:** Vitamin E, Nanoemulsion, Stability, Invivo bioavailability.

## 50 **1. Introduction**

51 Emulsion based delivery system is a good candidate for encapsulating and delivering  
52 lipophilic bioactive components such as nutraceuticals, micronutrients, catechins, DHA.<sup>1-8</sup>  
53 Vitamin E ( $\alpha$ -Tocopherol) is one of the nutraceutical compound, effectively used as an  
54 antioxidant and it prevents cancer and cardiovascular diseases.<sup>9</sup> Vitamin E is an oily liquid,  
55 with poor aqueous solubility and miscibility, which makes poor bioavailability. For any orally  
56 administered bioactive compound, bioavailability is depend on the dissolution rate in the  
57 intestinal lumen and absorption rate across the intestine. Hence these lipophilic bioactive  
58 compounds are usually administered as emulsion-based formulation to enhance their  
59 solubilization in the GI tract and to facilitate the biological uptake.<sup>10,11</sup> Further, Vitamin E is a  
60 nonpolar antioxidant, more effective in O/W emulsions as they retained in oil droplets. <sup>12</sup> Oil-  
61 in-water nanoemulsion have received great attention among the researchers because of their  
62 potential advantages like physical stability and enhanced bioavailability.<sup>13,14</sup>

63  
64 Saponin (Latin *sapo*, means soap), are biosurfactants, received its attention among the food  
65 researchers due to increasing evidence of their health benefits like inhibiting cholesterol  
66 absorption and decreasing the serum and liver cholesterol level.<sup>15,16</sup> Saponins are widely  
67 distributed in more than 500 plant species and used as surface active and foaming agents in  
68 the food and cosmetic industries. It is a glycoside - non ionic surfactant, containing hydrophilic  
69 part, composed of rhamnose, xylose, arabinose, galactose, fucose, and glucuronic acid; and  
70 the lipophilic portion consist of steroidal or triterpene structure.<sup>17,18</sup> Excellent reviews are  
71 available to read further about the extraction techniques<sup>19</sup>, isolation<sup>20</sup> and clinical  
72 significance<sup>21</sup> of saponins. Yang et al.<sup>22</sup> compared the effectiveness of saponin with synthetic

73 surfactant Tween 80 and suggested that natural surfactant is an effective surfactant and able  
74 to replace the synthetic surfactants. Wojciechowski et al.<sup>23</sup> studied the surface activity for  
75 saponin/ $\beta$ -casein mixture and reported that saponin can be used as a natural low molecular  
76 weight biosurfactant. Yang and McClements<sup>24</sup> and Ozturk et al.<sup>2</sup> successfully employed  
77 saponin surfactant for encapsulating vitamin D and E.

78

79 Oral administration of bioactive compounds is a most favored route among the consumers  
80 since it is easy to administer and requires low level of application skills. However, upon oral  
81 administration, a bioactive compound undergoes various physicochemical environment in the  
82 GI tract which influences the solubility, stability and bioavailability.<sup>11</sup> Many attempts have been  
83 made to understand the fate of emulsion during gastric digestion and their results showed that  
84 microstructural changes in emulsion during digestion are closely linked with digestion and  
85 release of nutrient in the digestive tract.<sup>25</sup> Hence, understanding the structure/stability of the  
86 ingested compound in the digestive environment helps in delivering the nutraceuticals  
87 effectively. *In vivo* and *in vitro* approaches are used for studying the fate of emulsified lipid  
88 within the GI tract. Various *in vitro* GI models have been developed to unravel the interesting  
89 structural and chemical changes of emulsion under simulated gastrointestinal condition.<sup>26,27</sup>  
90 But many *in vitro* models were failed to simulate the complex physicochemical and  
91 physiological events that happen in the GI tract.<sup>28</sup> However, it is undeniable that *in vivo* animal  
92 experiments are more time-consuming, costly and have ethical constraints. But they can  
93 provide most realistic and accurate results. Li et al.<sup>29</sup> studied the fate of emulsified lipids in the  
94 animal's gastrointestinal tract. Gallier et al.<sup>25,30</sup> unveiled the effect of milk processing on the  
95 digestion of milk fat globules with the animal model.

96

97 Food and Drug Administration (FDA) defines bioavailability as “the rate and the extent to

98 which the therapeutic moiety is absorbed and becomes available to the site of drug action".  
99 The overall bioavailability (F) of a lipophilic bioactive component depends on numerous  
100 factors and can be elucidated by the following equation<sup>31</sup>:

$$F = F_L \times F_A \times F_D \times F_M \times F_E$$

101 where  $F_L$  is the fraction of bioactive agent liberated into the gastrointestinal tract for  
102 absorption,  $F_A$  is the fraction that is absorbed by the intestinal epithelial cells,  $F_D$  is the fraction  
103 of bioactive agents that reaches the site of action after distribution amongst the various  
104 tissues of the body,  $F_M$  is the fraction that reaches the site of action in metabolically active  
105 form and  $F_E$  is the fraction of metabolically active bioactive component that remains at the site  
106 of action, i.e., without excretion. Song et al.<sup>9</sup> revealed the sustained release of vitamin E  
107 encapsulated by Ca-pectinate through *in vivo* animal study. Area under the curve (AUC) for  
108 the microencapsulated vitamin E increased about 118 % compared to free vitamin E, which  
109 proves the Ca-pectinate encapsulated vitamin E provided sustained-release and improved  
110 bioavailability. Food and Drug Administration has approved nanoemulsions for the clinical  
111 application of water-insoluble drugs. Gong et al.<sup>32</sup> observed 1.6 fold increase in bioavailability  
112 for the nanoemulsion to the marketed vitamin E soft capsules.

113

114 To the best of our knowledge, no demonstrated reports were available till date to prove  
115 nanoemulsion could enhance the oral bioavailability of vitamin E than the conventional  
116 emulsion. Therefore the current study has the following major aims: (1) to investigate the  
117 effect of thermal processing, storage and mechanical stress on the particle size distribution  
118 and appearance of conventional and nanoemulsions stabilized by natural surfactant saponin,  
119 (2) to study the impact of digestion on the structural changes of emulsion droplets in the  
120 gastrointestinal tract, and (3) to assess the influence of particle size on the oral bioavailability  
121 of vitamin E. The ultimate aim of this study is to facilitate the rationale usage of nanoemulsion

122 delivery system for utilization within the pharmaceutical and food industries.

123

## 124 **2. Experimental Methods**

125

### 126 **2.1. Chemicals**

127

128 Vitamin E ( $\alpha$ -Tocopherol) was purchased from HiMedia Laboratories Pvt Ltd, Mumbai,  
129 Saponin from Quillaja bark (powder form, active content 20-35 %) was purchased from  
130 Sigma-Aldrich, Mumbai. Sunflower oil was purchased from the local market. All other  
131 chemicals, reagents and solvents used were of analytical grade or HPLC grade. Milli-Q water  
132 was used for the preparation of emulsions and solvents.

133

### 134 **2.2. Emulsion Preparation**

135 **2.2.1. Nanoemulsion:** Vitamin E nanoemulsion was prepared by homogenizing 10% lipid  
136 phase (2 wt % vitamin E in sunflower oil) with 90% aqueous phase containing saponin (0.1  
137 wt %) and sodium azide (0.02 wt %). The aim of this study was to understand the effect of  
138 emulsion droplet size on the nutrient absorption. For this purpose the saponin concentration  
139 was maintained constant in all formulations and this approach would facilitate in studying the  
140 change in bioavailability profile of vitamin E based only on droplet size. Then, pre-emulsion  
141 was prepared by mixing these two phases using high-speed homogenizer (T18 Ultra Turrax,  
142 IKA India Pvt. Ltd.) at 15,500 rpm for 5 min at room temperature. Then, nanoemulsion was  
143 prepared by passing the pre-emulsion through the microfluidizier (Microfluidics, M110P,  
144 Diamond interaction chamber, MA, USA), at a chamber pressure of 12,000 psi for four cycles.

145 **2.2.2. Conventional emulsion:** Vitamin E conventional emulsion was prepared by passing  
146 the pre-emulsion through the microfluidizier (Microfluidics, M110P, Diamond interaction

147 chamber, MA, USA), for a single passage at the chamber pressure of 1,000 psi.

148

### 149 **2.3. Emulsion stability testing**

150

151 Stability of the prepared nanoemulsion and conventional emulsion to environmental stresses  
152 were studied

153

154 **2.3.1. Effect of thermal processing:** Emulsion samples were incubated in water bath at  
155 different temperatures (30 – 90 °C) for 30 min. Then samples were cooled to room  
156 temperature and stored at ambient temperature for 24 h prior to analysis.

157

158 **2.3.2. Long Term storage:** Emulsion samples were incubated in temperature controlled  
159 environment (5, 25 and 40 °C) for one month prior to analysis.

160

161 **2.3.3. Effect of mechanical stress:** Emulsions were subjected to a mechanical shaking test.  
162 Samples were placed randomly on a shaker and agitated at the maximum amplitude of 250  
163 strokes/min for 24 h at room temperature. At the end of each test, samples were analyzed for  
164 particle size and visually inspected for signs of phase separation.

165

166 **2.3.4. Stability in plasma:** An aliquot (0.05 mL) of each emulsion was mixed with 0.5 mL of  
167 blood plasma. Samples were then incubated at 37 C for 24 h. At the end of the experiment,  
168 samples were analyzed for particle size.

169

### 170 **2.4. Biological fate of emulsion**

171 The animal experiments were carried out at CSIR-CFTRI, Animal House Facility registered



172 with Committee for the Purpose of Control and Supervision of Experiments on Animals,  
173 Ministry of Environments, Forests and Climate Change, Government of India, New Delhi (No:  
174 49/1999/CPCSEA) established under The Prevention of Cruelty to Animals Act, 1960. The  
175 experimental protocols were approved by CFTRI - Institutional Animal Ethics Committee (No:  
176 IAEC/416/15). Male Wistar rats, weighing 200-220 g, were obtained from CSIR-CFTRI Animal  
177 House. Animals were adopted to laboratory conditions by keeping in temperature and  
178 humidity controlled animal observation room for 5 days. Prior to experiment, all animals were  
179 kept for overnight fasting and allowed free access to water. 1 ml of the sample (conventional  
180 and nanoemulsion) was administered into rat's stomach using feeding needle (Orchid  
181 Scientifics, Nashik, India). Samples were administered four times for every one hour. After  
182 one hour of the final administration, rats were sacrificed with diethyl ether. The  
183 gastrointestinal tract was removed and the digesta were collected from stomach and small  
184 intestine. Microstructural analysis for the digesta were observed using trinocular microscope  
185 (Olympus BX-5, ProgRes C-5 software) fixed with digital camera (ProgRes C-5) to capture  
186 images. All the samples were observed under 20X magnification.

187

## 188 **2.5. *In vivo* Bioavailability**

189

190 Male Wistar rats, weighing 200-220 g, were obtained from CSIR-CFTRI Animal House facility.  
191 Prior to experiment, all animals were kept for overnight fasting and allowed free access to  
192 water. To bring in further clarity to the role of droplet diameter in controlling the absorption of  
193 vitamin E, an additional emulsion sample with submicron sized droplet diameters (i.e. 679  
194 nm) was evaluated for its *in vivo* bioavailability. Briefly, rats were randomly divided into three  
195 groups (n= 3 per group): nanoemulsion, submicron emulsion and conventional emulsion for  
196 oral administration. Rats were administered a single dose of 100 mg/kg of freshly prepared

197 nanoemulsions, submicron emulsion and conventional emulsions. Blood samples (0.5 ml)  
198 were collected from retro-orbital vein at 0.5, 1, 2, 3, 4 and 6 h after oral administration.  
199 Immediately after blood collection, plasma was separated by centrifugation at 4000 rpm, 10  
200 min and stored at -20 °C till HPLC analysis. Mean plasma concentration of vitamin E versus  
201 time profiles were plotted and the pharmacokinetic parameters were determined by non-  
202 compartmental methods. The maximum plasma concentration ( $C_{max}$ ) and the time of  
203 maximum plasma concentration ( $T_{max}$ ) were determined directly from the measured data.  
204 Pharmacokinetic parameters like area under the curve (AUC), elimination rate constant ( $K_e$ ),  
205 elimination half-life ( $t_{1/2}$ ) were determined using PKSolver 2.0.<sup>33</sup>

206

## 207 **2.6. Analysis of vitamin E concentration in plasma**

208

209 Vitamin E concentration in the blood samples was determined via isocratic elution in HPLC  
210 system (Waters, Milford, USA), fitted with reverse phase Kromasil C18 column (4.6 mm x 250  
211 mm) was used. Plasma samples (100  $\mu$ l) were deproteinized with ethanol (300  $\mu$ l) and  
212 vortexed for 2 min. Then hexane (500  $\mu$ l) was added and centrifuged the mixture for 10 min at  
213 15000 rpm, then supernatant were transferred into amber vials. Hexane extraction procedure  
214 was repeated, and the collected organic layer were evaporated to dryness under stream of  
215 nitrogen. Prior to analysis, the residues were reconstituted in 100  $\mu$ l methanol. Elution were  
216 carried out at a flow rate of 1 ml/min under isocratic condition in the solvent ratio of methanol  
217 to water (98:2 v/v).

218

## 219 **2.7. Droplet characterization**

220

221 The average droplet size and size distribution of the emulsion formulation were determined by

222 laser diffraction particle size analyzer (S3500, Microtrac Inc., USA) using triple distilled water  
223 as dispersing medium. Emulsion droplet size was reported as the mean diameter of number  
224 distribution.

225

## 226 **2.8. Statistical Analysis**

227 All experimental works reported here were carried out in duplicates on the freshly prepared  
228 samples and the results were reported as averages and standard deviations of the  
229 measurements. Statistical analysis of the differences between various treatments was  
230 performed using paired Student's *t*-test. A 0.05 level of probability was taken as the level of  
231 significance. Area under the curve (AUC) for calculating release of vitamin E in the blood  
232 plasma was calculated by trapezoidal approximation.

233

## 234 **3. Results and Discussion**

235

### 236 **3.1. Effect of environmental stress on stability of conventional and nanoemulsion**

237

238 Nanoemulsions are heterogeneous systems consisting two immiscible liquids, nanometric  
239 sized oil droplets dispersed in an aqueous medium and stabilized by food-grade surfactant.  
240 However, the definition for nano is still in flux. Nanotechnology deals with the production,  
241 processing, and application of materials with sizes less than 1,000 nm.<sup>4</sup> The U.S. Food and  
242 Drug Administration (FDA) use a definition of 1-1000 nm for drugs and also European  
243 Medicines Agency defines nanoparticle in a size range of less than 1,000 nm. Based on these  
244 definitions, we considered the emulsion with average droplet diameter of around 280 nm as  
245 nanoemulsion, 500- 1000 as submicron emulsion and more than 1000 nm as conventional  
246 emulsion. Emulsion based system should remain stable throughout the anticipated shelf life of

247 the final product. Emulsion become unstable depend on the storage conditions such as pH,  
248 ionic strength, thermal processing, freeze-thaw cycle, drying and mechanical agitation.  
249 Emulsion undergo following instability mechanisms like flocculation, coalescence, Ostwald  
250 ripening and gravitational separation and become unstable.<sup>24</sup> Hence we examined the  
251 influence of environmental stresses on the stability of conventional and nanoemulsion.

252

253 **3.1.1. Thermal Processing:** The purpose of this experiment is to examine the influence of  
254 thermal processing on the stability of conventional and nanoemulsion (Fig. 2). Both emulsions  
255 were held at temperatures ranging from 30 to 90 °C for 30 min, then cooled to room  
256 temperature, and stored for 24 h. Creaming was not observed in any of the conventional and  
257 nanoemulsion after 24 h at room temperature. Furthermore, no significant change was  
258 observed in mean droplet diameter of the nanoemulsion. The stability of nanoemulsion at the  
259 elevated temperature might be attributed to the high enough electrostatic and steric repulsion  
260 among the droplets which prevented the droplet aggregation.<sup>34</sup> Similarly in the case of  
261 conventional emulsion slight change in droplet size were observed. However, we did see  
262 some instability in the conventional emulsion when they stored at elevated temperature for a  
263 period of 30 days (see next section). Our result suggests that conventional emulsion stable  
264 for a short duration thermal exposure and may become unstable to coalescence during the  
265 storage at elevated temperatures.

266

267 **3.1.2. Effect of long term storage and temperature:** For commercial applications of  
268 emulsion, the long-term stability, i.e., emulsion remain stable throughout their shelf-life is one  
269 of the most important factors.<sup>35</sup> Hence we examined the influence of storage time (30 day)  
270 and temperature (4, 25, 40 °C) on the stability of conventional and nanoemulsion. The  
271 stability of the samples during storage was determined by measuring mean particle diameter

272 (Table 1). There was insignificant increase in mean particle diameter for nanoemulsion after  
273 one month storage: the droplet size ranged from  $277 \pm 0.02$  to  $307 \pm 0.023$  nm (4 °C),  $277 \pm$   
274  $0.02$  to  $292 \pm 0.018$  nm (25 °C) and  $277 \pm 0.02$  to  $289 \pm 0.003$  nm (40 °C). These findings are  
275 agreed with those of Yang et al.<sup>24</sup> in Q-naturale stabilized oil-in-water emulsions stored at 5,  
276 37 and 55 °C for a period of one month. Increase in droplet size is attributed to the  
277 mechanisms like flocculation, coalescence and Ostwald ripening. In the case of conventional  
278 emulsions, decrease in the mean particle diameter was observed with increasing storage time  
279 for the samples stored at 4, 25 and 40 °C. This decrease in particle diameter might be due to  
280 the solubilization mechanism, movement of oil molecules from the emulsion droplets into the  
281 surfactant micelles. Furthermore, the rate of solubilization process is decreasing with reducing  
282 temperature from 40 to 4 °C, indicating that it took longer time for the vitamin E with sunflower  
283 oil to move from the emulsion droplets into surfactant micelles at lower temperature. These  
284 results are in agreement with Ziani et al.<sup>36</sup> who emphasized the reasons behind decrease in  
285 mean droplet diameter, (i) movement of oil from the emulsion droplets into swollen micelles,  
286 and (ii) growth of some droplets due to Ostwald ripening or coalescence that they became to  
287 big to detect.

288

289 **3.1.3. Stress testing and stability in plasma:** Vitamin E emulsion was developed with  
290 saponin (biosurfactant), a triterpene backbone structured molecule, with glucuronic acid and  
291 saccharides at C-3 and C-28 positions respectively. It contains triterpenoid or steroid  
292 backbone as hydrophobic part and saccharide residues, attached to the hydrophobic scaffold  
293 via glycoside bonds to act as a hydrophilic part.<sup>37</sup> To access their physical stability, the  
294 change in droplet size under mechanical agitation was monitored (Fig. 3). After 24 h of  
295 mechanical agitation, no visible free oil or phase separation of the emulsion was observed.  
296 Our results suggest that both conventional and nanoemulsion are stable under mechanical

297 stress.

298

299 Vitamin E homologs possess several biological activities in addition to their antioxidant  
300 properties. During acute clinical condition, oral administration of vitamin E is less effective for  
301 immediate increase in vitamin E concentration.<sup>38</sup> Hence parenteral formulation of vitamin E  
302 emulsion is advantageous for high risk patients. Stability of vitamin E emulsion droplets in  
303 plasma is an important factor for transdermal/intravenous applications. Flocculation and  
304 subsequent coalescence of emulsion droplets in the plasma and serum might cause adverse  
305 effects like blocking of lung capillaries.<sup>39</sup> Both conventional and nanoemulsion were stable  
306 after 24 h of incubation with plasma (Fig. 3). Nanoemulsion did not aggregate after 24 h of  
307 incubation with plasma, however when mixed with conventional emulsion increase in mean  
308 droplet size was observed, which may be due to the adsorption of plasma proteins onto the  
309 emulsion droplets. The adsorbed proteins can lead to flocculation of oil droplets by bridging  
310 and charge neutralization mechanisms.<sup>39</sup>

311

### 312 **3.2. Fate of emulsion in the digestive tract**

313 Fat digestion is a complex process involving several lipases acting in the stomach and small  
314 intestine and the intestinal uptake of fat soluble vitamins are highly dependent on the action of  
315 lipolytic enzymes on lipid substrates.<sup>40</sup> In the last decades, serious efforts have been made to  
316 understand the physicochemical changes of emulsion during digestion and the reports  
317 revealed that food emulsion undergo complicated physical and biochemical stresses.  
318 However, current understanding about the structural changes of emulsion is mainly based on  
319 the *in vitro* study using simulated gastric fluids. Digestion studies showed the microstructural  
320 changes like droplet flocculation, phase separation and bioaccessibility of nutrients.<sup>41</sup> By  
321 keeping in mind, the biological fate of conventional and nanoemulsion was studied in the

322 animal's gastrointestinal tract. Rats were fed with emulsion (1 ml) for a period of 4 hour with  
323 one hour interval. Then animal was sacrificed one hour after the final administration and the  
324 chyme and digesta was collected from stomach and small intestine respectively. Then the  
325 collected samples were examined using microscopy techniques without any further treatment  
326 to analyze microstructural changes during digestion (Fig. 4). For both conventional and  
327 nanoemulsion, strong evidence of droplet flocculation and coalescence were observed for the  
328 chyme samples collected from the stomach. Conventional emulsion become susceptible to  
329 flocculation in the presence of digestive enzymes which produces the distinct large droplets  
330 (see Fig. 4b). On the other hand, nanoemulsion ended with comparatively less flocculation  
331 followed by coalescence. Hence we observed lipid droplets in chyme ranges from 0.046-1.61  
332  $\mu\text{m}$  for conventional emulsion and 0.042-0.772  $\mu\text{m}$  for nanoemulsion gavaged rats. Similarly  
333 in the intestinal digesta, emulsion droplets are in the range of 0.047-1.867  $\mu\text{m}$  for the  
334 conventional emulsion and 0.042-0.619  $\mu\text{m}$  for the nanoemulsion.

335

336 In the stomach, the lipid droplets are exposed to highly acidic pH, mixed with digestive  
337 enzymes (gastric lipases for initiating lipid digestion and proteases for protein digestion) and  
338 experiences complex flow/force profile. After entering the small intestine, digestive enzymes  
339 act on the partially hydrolyzed lipids, like pancreatic lipase/co-lipase convert triglycerides and  
340 diglycerides into monoglycerides and free fatty acids, protease convert protein to peptides  
341 and aminoacids, phospholipases convert phospholipids to free fatty acids.<sup>31</sup> Further, gastric  
342 environment promotes the aggregation of emulsion droplets due to flocculation and/or  
343 coalescence and consequently the droplets are no longer in their original particle size<sup>42</sup> hence  
344 increase in droplet size was observed in this study. Gallier et al.<sup>25</sup> studied the behavior of  
345 proteins of raw cream and pasteurized milk cream during digestion, and reported that  
346 globules in the digesta are in the range of 1-35  $\mu\text{m}$  for raw cream and 1-40  $\mu\text{m}$  for pasteurized

347 cream. Similar results were observed for the *in vivo* digestion of  $\beta$ -lactoglobulin stabilized  
348 emulsion.<sup>29</sup> For the protein-stabilized emulsion, the proteolytic action of pepsin on the protein  
349 would reduce the droplet charge, which removes the steric repulsion barriers. This leads to  
350 aggregation and coalescence of emulsion droplets in the gastric environment.<sup>43</sup> In this study,  
351 emulsions were stabilized with saponin, which are stable to the acidic pH<sup>24</sup>, hence drastic  
352 increase in droplet size was not observed during digestion. The obtained results were in  
353 agreement with those of Marciani et al.<sup>44</sup> who reported that emulsion stabilized by non-ionic  
354 surfactant remain stable during the gastrointestinal digestion because of its high emulsion  
355 stability. Our results suggest that nanoemulsions are fairly resistant to droplet coalescence  
356 and breakdown in the gastrointestinal tract whereas conventional emulsions are highly  
357 susceptible for both droplet coalescence and breakdown, and saponin surfactant can be  
358 employed as an alternative for synthetic surfactant.

359

### 360 **3.3. *Invivo* bioavailability**

361

362 The mean plasma concentration versus time profiles of vitamin E in rats following oral  
363 administration of conventional, submicron and nanoemulsions were shown in Fig. 5. The  
364 pharmacokinetic parameters including half-time (h), maximum plasma concentration ( $\mu\text{g/ml}$ ),  
365 time to reach maximum plasma concentration (h), elimination rate constant ( $K_e$ ), area under  
366 the concentration-time curve ( $\text{AUC}_{0-t}$  and  $\text{AUC}_{0-\text{inf}}$ ) were calculated by non-compartment  
367 model (Table 2). Rats administered with conventional emulsion achieved maximum plasma  
368 concentration of 2.599  $\mu\text{g/ml}$  at 3 h, submicron emulsion achieved maximum plasma  
369 concentration of 7.236  $\mu\text{g/ml}$  at 3 h, whereas nanoemulsion achieved 11.253  $\mu\text{g/ml}$  at 2 h.  
370 Maximum plasma concentration ( $C_{\text{max}}$ ) was achieved at/before 3 h for all the administered  
371 formulation, hence the study was terminated at 6 h. Similarly half-life ( $t_{1/2}$ ) for conventional,



372 submicron and nanoemulsion were 1.11 h, 0.98 h and 0.848 h respectively. The  $t_{1/2}$  was  
 373 calculated using the equation  $t_{1/2}=0.693/K_e$  (where  $K_e$  is the elimination rate constant). The  
 374 results showed a higher  $C_{max}$  and shorter  $T_{max}$  for the oral administration of nanoemulsion  
 375 than the conventional and submicron emulsion. The increase in  $C_{max}$  indicates that the  
 376 nanoemulsion was effectively increasing the vitamin E absorption. The area under the curve  
 377 ( $AUC_{0-inf}$ ) of the vitamin E nanoemulsion, submicron and conventional emulsion were 22.294,  
 378 17.686 and 7.476  $\mu\text{g/ml/h}$  respectively. Thus our data suggested that the degree of exposure  
 379 to nano-, submicron emulsion showed 3, 2.4-fold increase in bioavailability respectively,  
 380 which demonstrates nanoemulsion formulation was able to increase the oral bioavailability of  
 381 vitamin E.

382

383 Absorption of bioactive compound is depend on two factors: (i) solubility in the gastrointestinal  
 384 lumen, and (ii) capacity to diffuse across the enterocytes.<sup>45</sup> Emulsion-based delivery system  
 385 was formulated to overcome the solubilization problem. The oral bioavailability of natural  
 386 vitamin E is not high<sup>32,46</sup>; however the nanoemulsion formulation enhanced the bioavailability  
 387 of vitamin E by increasing its solubility. Mass flux across the intestine can be be elucidated by  
 388 the following equation:<sup>10</sup>

$$\frac{dm}{dt} = A \times P_{PT} \times C_{lumen} + \frac{V_{max(influx)} \times C_{lumen}}{K_m(influx) + C_{lumen}} - \frac{V_{max(efflux)} \times C_{ent}}{K_m(efflux) + C_{ent}}$$

389 where A is the surface area of membrane,  $P_{PT}$  is the passive permeability,  $C_{lumen}$  is the  
 390 intestinal luminal concentration,  $C_{ent}$  is the concentration of bioactive inside the enterocytes,  
 391  $K_m$  is the Michaelis-Menten constant of the compound with the influx or the efflux and  $V_{max}$  is  
 392 the maximum efflux or influx mediated transport. Abuasal et al.<sup>10,47</sup> reported that total flux of  
 393 vitamin E is only by the contribution of passive and carrier mediated transport, and the above  
 394 mass flux equation can be expressed as:

$$\frac{dm}{dt} = A \times P_{PT} \times C_{\text{lumen}} + \frac{V_{\text{max(influx)}} \times C_{\text{lumen}}}{K_{m(\text{influx})} + C_{\text{lumen}}}$$

395 Thus the overall absorption rate of vitamin E is determined by the contribution of saturable  
396 (carrier mediated transport) and unsaturable (passive transport) processes. Further, the  
397 saturable process is mediated by the Niemann-Pick C1-like 1 (NPC1L1) transporter, a  
398 polytopic protein present on the intestinal epithelial cells that facilitates the vitamin E  
399 absorption.<sup>48</sup> The uptake of vitamin E is saturated by NPC1L1 transporter, thus the oral  
400 bioavailability is decreasing. To overcome this, new formulation approaches like solid lipid  
401 nanoparticles (SLN), lipid based formulations like self-emulsifying drug delivery systems  
402 (SEDDS), nanoemulsion have been used to enhance its permeability, thus its oral  
403 bioavailability. Abuasal et al.<sup>49</sup> reported that solid lipid nanoparticles enhanced the  
404 bioavailability of  $\gamma$ -Tocotrienol (member of vitamin E family) by ten-fold compared to the  
405 control given as mixed micelles. *In vivo* pharmacokinetic studies also revealed higher plasma  
406 concentration of  $\gamma$ -Tocotrienol for SLN formulation ( $938 \pm 63$  ng/ml) compared to control ( $212$   
407  $\pm 111$  ng/ml). Gong et al.<sup>32</sup> compared the oral bioavailability for the vitamin E nanoemulsion  
408 with marketed soft capsules and reported AUC for the nanoemulsion and marketed soft  
409 capsules were 1.48 and 0.907  $\mu\text{g/ml/h}$  respectively. Increased bioavailability for the  
410 nanoemulsion might be due to the small-sized droplets offered larger surface area, which  
411 enabled large number of lipase molecules to bind at the oil-water interface. Armand et al.<sup>42</sup>  
412 reported 3.3 times higher lipolysis for the fine emulsion than the coarse emulsion. Still, the  
413 effect of formulation on vitamin E metabolism needs to be addressed by comparing the  
414 metabolites between conventional and nanoemulsion.

415

#### 416 4. Conclusions

417

418 This study mainly focused on understanding the role of emulsion particle size on the stability,  
419 digestibility and bioavailability of colloidal dispersion containing vitamin E and natural  
420 surfactant (saponin). High-pressure homogenization technique was employed for the  
421 formation of conventional and nanoemulsion with droplet diameters 1,285 nm and 277 nm  
422 respectively. Both conventional and nanoemulsion were stable at short duration (30 min) of  
423 thermal exposure, temperature ranging from 30 to 90 °C. During long term storage (30 days)  
424 at different thermal conditions (4, 25, 40 °C), nanoemulsion was physically stable with a slight  
425 increase in mean particle diameter. Both conventional and nanoemulsion were stable with no  
426 visible free oil or phase separation after 24 h of mechanical agitation. However conventional  
427 emulsion aggregated in plasma after 24 h of incubation due to adsorption of plasma proteins  
428 onto the emulsion droplets. In the digestive tract, chyme of nanoemulsion had comparatively  
429 less flocculation followed by coalescence than the conventional emulsion. Pharmacokinetic  
430 study in rats revealed an increase in bioavailability for nanoemulsions; area under the curve  
431 ( $AUC_{0-\infty}$ ) of the vitamin E nano-, submicron and conventional emulsions were 22.294, 17.68  
432 and 7.476  $\mu\text{g/ml/h}$  respectively, which proved an increase in bioavailability by 3 fold for  
433 nanoemulsion. These results help in designing and producing vitamin E colloidal delivery  
434 system based on nanoemulsions for utilization in the pharmaceutical and food industries.

435

436

#### 437 **ACKNOWLEDGMENT**

438 Authors wish to thank Prof. Ram Rajasekharan, Director, CSIR-CFTRI, Mysore, India for his  
439 support and encouragement. The author (Parthasarathi) thanks the ICMR, India for awarding  
440 SRF fellowship.

441

442 **References**

- 443 1 G. Davidov-Pardo and D. J. McClements, *Food Chem.*, 2015, 167, 205–212.
- 444 2 B. Ozturk, S. Argin, M. Ozilgen and D. J. McClements, *Food Chem.*, 2015, 187, 499–  
445 506.
- 446 3 P. Karthik, P. N. Ezhilarasi and C. Anandharamakrishnan, *Crit. Rev. Food Sci. Nutr.*,  
447 2015. DOI:10.1080/10408398.2015.1006767
- 448 4 P. N. Ezhilarasi, P. Karthik, N. Chhanwal and C. Anandharamakrishnan, *Food*  
449 *Bioprocess Technol.*, 2013, 6, 628–647.
- 450 5 P. Karthik and C. Anandharamakrishnan, *Food Bioprocess Technol.*, 2013, 6, 2780–  
451 2790.
- 452 6 C. Anandharamakrishnan, *Techniques for Nanoencapsulation of Food Ingredients*,  
453 Springer New York, New York, NY, 2014.
- 454 7 J. A. Bhushani, P. Karthik and C. Anandharamakrishnan, *Food Hydrocoll.*, 2016, 56,  
455 372–382.
- 456 8 P. Karthik and C. Anandharamakrishnan, *RSC Adv.*, 2016, 6, 3501–3513.
- 457 9 Y. Bin Song, J. S. Lee and H. G. Lee, *Colloids Surfaces B Biointerfaces*, 2009, 73, 394–  
458 398.
- 459 10 B. S. Abuasal, H. Qosa, P. W. Sylvester and A. Kaddoumi, *Biopharm. Drug Dispos.*,  
460 2012, 33, 246–256.
- 461 11 Y. Ting, Y. Jiang, C. T. Ho and Q. Huang, *J. Funct. Foods*, 2014, 7, 112–128.
- 462 12 S. S. Kiralan, E. Doğu-Baykut, K. Kittipongpittaya, D. J. McClements and E. A. Decker,  
463 *J. Agric. Food Chem.*, 2014, 62, 10561–10566.
- 464 13 M. Fanun, *Soft Mater.*, 2009, 7, 258–276.
- 465 14 Q. Huang, H. Yu and Q. Ru, *J. Food Sci.*, 2010, 75, R50–R57.
- 466 15 L. Vinarova, Z. Vinarov, V. Atanasov, I. Pantcheva, S. Tcholakova, N. Denkov and S.

- 467 Stoyanov, *Food Funct.*, 2015, 6, 501–512.
- 468 16 L. Vinarova, Z. Vinarov, B. Damyanova, S. Tcholakova, N. Denkov and S. Stoyanov,  
469 *Food Funct.*, 2015, 6, 1319–1330.
- 470 17 W. Oleszek and A. Hamed, in *Surfactants from Renewable Resources*, John Wiley &  
471 Sons, Ltd, Chichester, UK, pp. 239–249.
- 472 18 K. Golemanov, S. Tcholakova, N. Denkov, E. Pelan and S. D. Stoyanov, *Soft Matter*,  
473 2014, 10, 7034–7044.
- 474 19 C. Y. Cheok, H. A. K. Salman and R. Sulaiman, *Food Res. Int.*, 2014, 59, 16–40.
- 475 20 R. A. Hill and J. D. Connolly, *Nat. Prod. Rep.*, 2013, 30, 1028–1065.
- 476 21 H. Sheng and H. Sun, *Nat. Prod. Rep.*, 2011, 28, 543–593.
- 477 22 Y. Yang, M. E. Leser, A. A. Sher and D. J. McClements, *Food Hydrocoll.*, 2013, 30,  
478 589–596.
- 479 23 K. Wojciechowski, A. Kezwon, J. Lewandowska and K. Marcinkowski, *Food Hydrocoll.*,  
480 2014, 34, 208–216.
- 481 24 Y. Yang and D. J. McClements, *Food Chem.*, 2013, 141, 473–481.
- 482 25 S. Gallier, J. Cui, T. D. Olson, S. M. Rutherford, A. Ye, P. J. Moughan and H. Singh,  
483 *Food Chem.*, 2013, 141, 3273–3281.
- 484 26 F. Kong and R. P. Singh, *J. Food Sci.*, 2008, 73.
- 485 27 S. J. Hur, B. O. Lim, E. A. Decker and D. J. McClements, *Food Chem.*, 2011, 125, 1–12.
- 486 28 L. Chen, X. Wu and X. D. Chen, *J. Food Eng.*, 2013, 117, 183–192.
- 487 29 Y. Li, J. Kim, Y. Park and D. J. McClements, *Food Funct.*, 2012, 3, 528.
- 488 30 S. Gallier, X. Q. Zhu, S. M. Rutherford, A. Ye, P. J. Moughan and H. Singh, *Food*  
489 *Chem.*, 2013, 141, 3215–3223.
- 490 31 D. J. McClements and H. Xiao, *Food Funct.*, 2012, 3, 202–220.
- 491 32 Y. Gong, Y. Wu, C. Zheng, L. Fan, F. Xiong and J. Zhu, *AAPS PharmSciTech*, 2012, 13,

- 492 961–966.
- 493 33 Y. Zhang, M. Huo, J. Zhou and S. Xie, *Comput. Methods Programs Biomed.*, 2010, 99,  
494 306–314.
- 495 34 B. Ozturk, S. Argin, M. Ozilgen and D. J. McClements, *J. Food Eng.*, 2014, 142, 57–63.
- 496 35 A. H. Saberi, Y. Fang and D. J. McClements, *J. Colloid Interface Sci.*, 2013, 391, 95–  
497 102.
- 498 36 K. Ziani, Y. Fang and D. J. McClements, *Food Res. Int.*, 2012, 46, 209–216.
- 499 37 R. Stanimirova, K. Marinova, S. Tcholakova, N. D. Denkov, S. Stoyanov and E. Pelan,  
500 *Langmuir*, 2011, 27, 12486–98.
- 501 38 A. Lassnigg, A. Punz, R. Barker, P. Keznickl, N. Manhart, E. Roth and M. Hiesmayr, *Br.*  
502 *J. Anaesth.*, 2003, 90, 148–154.
- 503 39 J. Han, S. S. Davis, C. Papandreou, C. D. Melia and C. Washington, *Pharm. Res.*, 2004,  
504 21, 1573–1580.
- 505 40 M. Armand, P. Borel, B. Pasquier, C. Dubois, M. Senft, M. Andre, J. Peyrot, J. Salducci  
506 and D. Lairon, *Am. J. Physiol.*, 1996, 271, G172–G183.
- 507 41 L. Mao and S. Miao, *Food Eng. Rev.*, 2015, 7, 439–451.
- 508 42 M. Armand, B. Pasquier, M. André, P. Borel, M. Senft, J. Peyrot, J. Salducci, H.  
509 Portugal, V. Jaussan and D. Lairon, *Am. J. Clin. Nutr.*, 1999, 70, 1096–1106.
- 510 43 A. Sarkar, K. K. T. Goh, R. P. Singh and H. Singh, *Food Hydrocoll.*, 2009, 23, 1563–  
511 1569.
- 512 44 L. Marciiani, M. Wickham, G. Singh, D. Bush, B. Pick, E. Cox, A. Fillery-Travis, R.  
513 Faulks, C. Marsden, P. A. Gowland and R. C. Spiller, *AJP Gastrointest. Liver Physiol.*,  
514 2007, 292, G1607–G1613.
- 515 45 G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R.-O.  
516 Quinkert, F. Martin and C. Müller-Goymann, *Pharm. Res.*, 2010, 27, 1469–1486.

- 517 46 R. J. Sokol, N. Butler-Simon, J. E. Heubi, S. T. Iannaccone, H. J. McClung, F. Accurso,  
518 K. Hammond, M. Heyman, F. Sinatra, C. Riely, J. Perrault, J. Levy and A. Silverman,  
519 Ann. N. Y. Acad. Sci., 1989, 570, 156–169.
- 520 47 B. Abuasal, P. W. Sylvester and A. Kaddoumi, Drug Metab. Dispos., 2010, 38, 939–945.
- 521 48 K. Narushima, T. Takada, Y. Yamanashi and H. Suzuki, Mol. Pharmacol., 2008, 74, 42–  
522 49.
- 523 49 B. S. Abuasal, C. Lucas, B. Peyton, A. Alayoubi, S. Nazzal, P. W. Sylvester and A.  
524 Kaddoumi, Lipids, 2012, 47, 461–469.
- 525
- 526
- 527
- 528
- 529
- 530
- 531
- 532
- 533
- 534
- 535
- 536
- 537
- 538
- 539
- 540
- 541

542

543

544 **Captions:**

545

546 **Table 1:** Particle size changes after one month storage at different conditions547 **Table 2:** Pharmacokinetic parameters after oral administration of conventional, submicron  
548 and nanoemulsions549 **Fig. 1** Particle size distribution of the vitamin E conventional emulsions and nanoemulsions550 **Fig. 2** Influence of thermal processing on the mean particle diameter of conventional and  
551 nanoemulsions552 **Fig. 3** Stability of Vitamin E nanoemulsion and conventional emulsion against plasma and  
553 mechanical stress at 24 hrs incubation at 37 °C. Mean (n=6) ± SD.554 **Fig. 4** Fate of emulsion in the digestive tract. (a) Microscopic image of conventional emulsion;  
555 (b) Gastric chyme collected after 60 min after gavaging with conventional emulsion; (c) Small  
556 intestinal digesta of rats gavaged with conventional emulsion; (d) Microscopic image of  
557 nanoemulsion; (e) Gastric chyme collected after 60 min after gavaging with nanoemulsion; (f)  
558 Small intestinal digesta of rats gavaged with nanoemulsion.559 **Fig. 5** Plasma concentration (µg/ml) versus time (h) profiles after oral administration of  
560 vitamin E conventional and nanoemulsion in rats (n=3).

561

562

563

564

565

566



567

568

569 **Table 1** Particle size changes after one month storage at different conditions

570

571

		0 Day	After one month
Conventional emulsion	4 °C	1.285 ± 0.003	1.253 ± 0.056
	25 °C		0.988 ± 0.009
	40 °C		0.537 ± 0.083
Nanoemulsion	4 °C	0.277 ± 0.02	0.307 ± 0.023
	25 °C		0.292 ± 0.018
	40 °C		0.289 ± 0.003

572

573

574

575

576

577

578

579

580

581

582

583

584

585 **Table 2** Pharmacokinetic parameters after oral administration of conventional, submicron and

586 nanoemulsion

587

Pharmacokinetic parameters <sup>(a)</sup>	Conventional emulsion	Submicron emulsion	Nanoemulsion
C <sub>max</sub> (µg/ml)	2.599	7.236	11.253
T <sub>max</sub> (h)	3.0	3.0	2.0
K <sub>e</sub>	0.622	0.707	0.817
Half life (h)	1.11	0.98	0.848
AUC <sub>0-t</sub> (µg/ml/h)	6.872	16.534	21.791
AUC <sub>0-inf</sub> (µg/ml/h)	7.476	17.686	22.294

588

589 <sup>(a)</sup> Data were collected using non-compartmental analysis

590

591

592

593

594

595

596

597


598

599

600 **Fig. 1** Particle size distribution of the vitamin E conventional and nanoemulsion

601

602



603

604

605

606

607

608

609

610

611

612

613

614

615 **Fig. 2** Influence of thermal processing on mean particle diameters of conventional and  
616 nanoemulsion.

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632


633

634

635

636

637



638


639

640 **Fig. 3** Stability of Vitamin E nanoemulsion and conventional emulsion against plasma and  
641 mechanical stress at 24 hrs incubation at 37 °C. Mean (n=6) ± SD.

642

643

644



656

657

658

659

660

661


662

663

664

665 **Fig. 4** Fate of emulsion droplets in the digestive tract. (a) Microscopic image of conventional  
666 emulsion; (b) Gastric chyme collected after 60 min after gavaging with conventional emulsion;  
667 (c) Small intestinal digesta of rats gavaged with conventional emulsion; (d) Microscopic image  
668 of nanoemulsion; (e) Gastric chyme collected after 60 min after gavaging with nanoemulsion;  
669 (f) Small intestinal digesta of rats gavaged with nanoemulsion.

670



671

672

673

674

675


676

677

678 **Fig. 5** Plasma concentration ( $\mu\text{g/ml}$ ) versus time (h) profiles after oral administration of  
679 vitamin E conventional, submicron and nanoemulsion in rats (n=3).

680

681



682

683

684

685


686

687

688

689

690



237x146mm (96 x 96 DPI)